Juno reports updated Phase I DLBCL data for JCAR017

Juno Therapeutics Inc. (NASDAQ:JUNO) reported updated data from the Phase I TRANSCEND NHL 001 trial of JCAR017 in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). The data were released in an abstract ahead of the American Society of Hematology meeting in Atlanta next month.

Among 68 evaluable DLBCL patients, JCAR017 led to a best overall response rate (ORR) of 75%, with 3- and 6-month response rates of 49% and 40%, respectively. The best overall complete response (CR) rate was 56%, with 3- and 6-month CR rates of 40% and 37%, respectively. The median duration of response was 5 months, median duration of CR was 9.2 months and median overall survival (OS) was 13.7 months. The 6-month OS rate was 75% at a median follow-up of 5.8 months...